Evidence map›Paper›PMID 35152272›Full record

Trial reportProstate cancer and prostatic diseases2022

Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth.

Jin-Soo Kim, Dennis R Taaffe, Daniel A Galvão, Nicolas H Hart, Elin Gray, Charles J Ryan, Stacey A Kenfield, Fred Saad, Robert U Newton

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Prostate cancer and prostatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 4 pooled it
6.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Article
  11. History informing the future of exercise oncology.Journal of the National Cancer Institute. Monographs · 2025
    Review
  12. Article
  13. Formation of a β-Endorphin Corona Mitigates Alzheimer's Amyloidogenesis.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Jin-Soo KimExercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, 6027, Australia.
Dennis R TaaffeExercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, 6027, Australia.ORCID http://orcid.org/0000-0001-6381-1597
Daniel A GalvãoExercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, 6027, Australia.ORCID http://orcid.org/0000-0002-8209-2281
Nicolas H HartExercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, 6027, Australia.
Elin GraySchool of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, 6027, Australia.
Charles J RyanMedical School, University of Minnesota, Minneapolis, MN, 55455, USA.ORCID http://orcid.org/0000-0002-2081-3557
Stacey A KenfieldDepartments of Urology and Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, 94143, USA.ORCID http://orcid.org/0000-0002-1585-7352
Fred Saad *Department of Urology, Centre Hospitalier de l'Université de Montréal, Montréal, QC, H2X 3E4, Canada.ORCID http://orcid.org/0000-0003-2986-5617
Robert U Newton *Exercise Medicine Research Institute, Edith Cowan University, Joondalup, WA, 6027, Australia. r.newton@ecu.edu.au.ORCID http://orcid.org/0000-0003-0302-6129
Edith Cowan University · AUCentre Hospitalier de l’Université de Montréal · CAUniversity of California, San Francisco · USUniversity of Minnesota Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAltering the systemic milieu through exercise has been proposed as a potential mechanism underlying exercise-driven tumour suppression. It is not yet known whether men with advanced prostate cancer can elicit such adaptations following a program of exercise. The purpose is to examine myokine levels of serum acquired from metastatic castrate-resistant prostate cancer (mCRPC) patients recruited to the INTERVAL-GAP4 trial before and after 6 months of exercise and its tumour-suppressive effect.

methodsTwenty-five men with mCRPC (age = 74.7 ± 7.1 yrs) were randomised to supervised multimodal (aerobic and resistance) exercise (EX) or self-directed exercise control group (CON). Body composition was assessed using dual-energy x-ray absorptiometry (DXA), and fasting blood in a rested state was collected at baseline and at 6 months. Serum levels of myokines (SPARC, OSM, decorin, IGF-1, and IGFBP-3) were measured. Serum was applied to the prostate cancer cell line DU145, and growth was assessed for 72 h.

resultsNo significant change in body composition was observed. Adjusted serum OSM (P = 0.050) and relative OSM (P = 0.083), serum SPARC (P = 0.022) and relative SPARC (P = 0.025) increased in EX compared to CON. The area under curve (AUC) over 72 h showed a significant reduction in DU145 growth after applying post-intervention serum from the EX vs CON (P = 0.029).

conclusionElevated myokine expressions and greater tumour-suppressive effects of serum after 6 months of periodised and autoregulated supervised exercise was observed in men with mCRPC. Exercise-induced systemic changes may slow disease progression in men with advanced prostate cancer.

Indexed as

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overBody CompositionCell ProliferationExerciseExercise TherapyHumansMale

Identifiers

PMID35152272
PMCPMC8853098
OpenAlexW4211072433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.